Yüklüyor......
Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials
BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor ligand, has shown survival benefits in the treatment of many types of malignant tumors, including non-small-cell lung cancer (NSCLC). We conducted this systematic review and meta-analysis to investigate the ris...
Kaydedildi:
| Yayımlandı: | Onco Targets Ther |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4844428/ https://ncbi.nlm.nih.gov/pubmed/27143937 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S96156 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|